Platelet-derived growth factor improves cardiac function in a rodent myocardial infarction model

Area of Science:

• Cardiovascular Research
• Regenerative Medicine
• Preclinical Studies

Background:

• Effective cardioprotective therapies for myocardial infarction (MI) require preclinical validation of improved cardiac function post-coronary occlusion.
• Previous research demonstrated that platelet-derived growth factor (PDGF) pretreatment promotes angiogenesis and reduces myocardial injury in rodent models.
• The current study investigates the correlation between histological findings and noninvasive cardiac function assessments following PDGF pretreatment.

Purpose of the Study:

• To determine the correlation between histological evidence of reduced myocardial injury and noninvasive measures of improved cardiac function after PDGF pretreatment.
• To evaluate the efficacy of PDGF as a cardioprotective agent in a preclinical model of acute myocardial infarction.

Main Methods:

• Rats received intramyocardial injections of PDGF or phosphate-buffered saline (PBS) 24 hours before permanent ligation of the left anterior descending artery.
• Myocardial injury was assessed by Masson's trichrome staining 14 days post-ligation.
• Cardiac function was evaluated noninvasively using electrocardiography, exercise testing, and echocardiography, and correlated with histological outcomes.

Main Results:

• PDGF pretreatment resulted in significantly lower ST-segment elevation during coronary occlusion compared to PBS controls (0.12 ± 0.02 mV vs. 0.35 ± 0.05 mV, P < 0.05).
• Exercise testing 14 days post-occlusion showed faster maximal exercise speeds in PDGF-treated rats (28.54 ± 3.98 m/min) versus controls (24.98 ± 3.13 m/min, P < 0.05).
• Echocardiography revealed significantly greater left ventricular fractional shortening in PDGF-pretreated rats (18.47 ± 12.21%) compared to controls (4.91 ± 7.21%, P < 0.05).

Conclusions:

• Pretreatment with platelet-derived growth factor (PDGF) demonstrably improves cardiac function following acute coronary occlusion in a preclinical setting.
• These findings support the potential of PDGF-based strategies as a significant advancement in the therapeutic approach to myocardial infarction.
• The study establishes a correlation between histological improvements and enhanced physiological cardiac function, validating PDGF's cardioprotective effects.